Diagnostic company Exact Sciences Corporation (NASDAQ: EXAS) will be reporting results tomorrow after the bell. Here’s what to look for.
Exact Sciences beat analysts’ revenue expectations by 1.6% last quarter, reporting revenues of $713.4 million, up 10.3% year on year. It was a strong quarter for the company, with a solid beat of analysts’ constant currency revenue estimates and an impressive beat of analysts’ EPS estimates.
Is Exact Sciences a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Exact Sciences’s revenue to grow 8% year on year to $688.5 million, improving from the 5.8% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.10 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Exact Sciences has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.7% on average.
Looking at Exact Sciences’s peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Regeneron’s revenues decreased 3.7% year on year, missing analysts’ expectations by 6.1%, and Incyte reported revenues up 19.5%, topping estimates by 6.4%.
Read our full analysis of Regeneron’s results here and Incyte’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Exact Sciences is up 2.4% during the same time and is heading into earnings with an average analyst price target of $66.85 (compared to the current share price of $44.50).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
